<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Paediatr Respir Rev</journal-id><journal-id journal-id-type="iso-abbrev">Paediatr Respir Rev</journal-id><journal-title-group><journal-title>Paediatric Respiratory Reviews</journal-title></journal-title-group><issn pub-type="ppub">1526-0542</issn><issn pub-type="epub">1526-0550</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7301825</article-id><article-id pub-id-type="publisher-id">S1526-0542(20)30095-6</article-id><article-id pub-id-type="doi">10.1016/j.prrv.2020.06.010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Vaccines for COVID-19: the current state of play</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Koirala</surname><given-names>Archana</given-names></name><email>Archana.Koirala@health.nsw.gov.au</email><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Jin Joo</surname><given-names>Ye</given-names></name><email>YeJin.Joo@health.nsw.gov.au</email><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Khatami</surname><given-names>Ameneh</given-names></name><email>ameneh.khatami@health.nsw.gov.au</email><xref rid="af015" ref-type="aff">c</xref><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Chiu</surname><given-names>Clayton</given-names></name><email>clayton.chiu@health.nsw.gov.au</email><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Britton</surname><given-names>Philip N</given-names></name><email>philip.britton@health.nsw.gov.au</email><xref rid="af015" ref-type="aff">c</xref><xref rid="af020" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005"><label>a</label>National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia</aff><aff id="af010"><label>b</label>Department of Infectious Diseases, Nepean Hospital, Penrith, NSW, Australia</aff><aff id="af015"><label>c</label>Sydney Medical School, the University of Sydney, NSW, Australia</aff><aff id="af020"><label>d</label>Department of Infectious Diseases and Microbiology, the Children&#x02019;s Hospital at Westmead, NSW, Australia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: C/o Discipline Child and Adolescent Heath, The Children&#x02019;s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia. <email>philip.britton@health.nsw.gov.au</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>18</day><month>6</month><year>2020</year></pub-date><history><date date-type="received"><day>11</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab005"><p>There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 &#x02013; the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges of developing and deploying a new vaccine on a global scale, and recommend caution with respect to our expectations of the timeline that may be ahead.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Covid 19</kwd><kwd>vaccines</kwd><kwd>human trials</kwd><kwd>timeline</kwd></kwd-group></article-meta></front><body><sec id="s0005"><title>Introduction:</title><p id="p0005">COVID-19 is the disease caused by a novel betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The disease was first reported in December 2019 Wuhan, China <xref rid="b0005" ref-type="bibr">[1]</xref> and the full genome was sequenced and published by January 05, 2020 <xref rid="b0010" ref-type="bibr">[2]</xref>. By March 11, 2020, COVID-19 had spread globally and was declared a pandemic, with, at the time of writing, June 6<sup>th</sup> 2020, there has been over 6 million people infected and 380,000 deaths <xref rid="b0015" ref-type="bibr">[3]</xref>.</p><p id="p0010">The disease primarily affects the respiratory tract and disease severity can range from very mild rhinorrhoea to severe acute respiratory distress syndrome and death <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>. A substantial minority of infections are asymptomatic. Non-respiratory symptoms such as anosmia, diarrhoea, rash, thromboembolic disorders, myocarditis and vasculitis have also been associated with COVID-19 <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>. The median incubation period is estimated to be 5 days with a majority developing symptoms by 11.5 days <xref rid="b0070" ref-type="bibr">[14]</xref>. COVID-19 patients have been shown to excrete viral nucleic acid at highest levels at the onset of symptoms <xref rid="b0075" ref-type="bibr">[15]</xref>. This, and other epidemiological data <xref rid="b0080" ref-type="bibr">[16]</xref> suggests transmissibility within an as yet undefined pre-symptomatic period <xref rid="b0080" ref-type="bibr">[16]</xref>. Clinical deterioration is usually delayed into the second week of illness and associated with laboratory features of an immune-mediated cytokine storm causing widespread inflammation and disseminated intravascular coagulation, usually with low level viraemia <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>.</p><p id="p0015">The case fatality rate (death amongst persons with disease) is consistently reported to be age dependent, with a higher percentage in elderly (aged &#x0003e;70 years) cases dying, although other factors are also associated with intensive care admission and mortality <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref> including sex (male&#x0003e;female), hypertension, obesity and diabetes. The reported case fatality rates [CFR] have been between 0.82% and 9.64%, with variability in CFR likely due to the testing frequency and access as well as other health system capacity factors in different locations <xref rid="b0100" ref-type="bibr">[20]</xref>. The infection fatality rate (IFT; death amongst all people infected &#x02013; asymptomatic and not tested) is a better estimate of population mortality and is modelled to be between 0.1% to 0.41% <xref rid="b0100" ref-type="bibr">[20]</xref>.</p><p id="p0020">SARS-CoV-2 is one of three coronaviruses that may cause severe respiratory diseases, including fatality, in humans and have been associated with major outbreaks in the last 20 years; the other two viruses being severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV and MERS-CoV (MERS-CoV). Although there were some development of vaccines against SARS and MERS, including a small number of human phase 1 clinical trials, there are no licenced vaccines for any coronavirus as yet.</p><p id="p0025">In addition to these novel epidemic viruses with zoonotic origins, there are four other endemic human coronaviruses in circulation, HCoV2-229E, -HKU1, -NL63 and -OC43 all predominantly causing mild symptoms of the common cold <xref rid="b0105" ref-type="bibr">[21]</xref>.</p></sec><sec id="s0010"><title>History of vaccines for Coronaviruses:</title><p id="p0030">Coronaviruses have a large (30+ kb) single-stranded positive sense RNA genome encased by a helical nucleocapsid (N) and an outer envelope comprised of matrix protein (M), envelope protein (E) and spike proteins (S) <xref rid="b0110" ref-type="bibr">[22]</xref>. The S protein, which naturally occurs in a trimeric form, contains the receptor-binding domain (RBD) responsible for binding onto the angiotensin converting enzyme 2 (ACE2) and entry into the cell (<xref rid="f0005" ref-type="fig">Figure 1</xref>
). In SARS-CoV, of all the structural proteins, S protein was found to elicit neutralising antibody and is a major target antigen for vaccine development <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>.<fig id="f0005"><label>Figure 1</label><caption><p>Schematic of the structure of SARS-CoV2. <italic>(Adapted from Lee, C-Y et al, Frontiers in Immunology, 2020)</italic><xref rid="b0500" ref-type="bibr">[100]</xref>.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0035">There have been difficulties in the development of coronavirus vaccines historically. Coronavirus vaccines in animal models that mimic human disease have been immunogenic but generally not shown to effectively prevent acquisition of disease <xref rid="b0125" ref-type="bibr">[25]</xref>. Further, there is a concern that vaccination, as with natural coronaviral infection, may not induce long lived immunity and re-infection may be possible <xref rid="b0130" ref-type="bibr">[26]</xref>. In some ways more concerning has been vaccine associated disease enhancement. Previous use of coronavirus vaccines (SARS-CoV and MERS-CoV) in some animal models raised safety concerns regarding Th2 mediated immunopathology <xref rid="b0135" ref-type="bibr">[27]</xref>. Mice vaccinated with two inactivated whole virus vaccines, a recombinant DNA spike protein vaccine or a virus-like particle vaccine developed lung pathology including eosinophilic infiltration 2 days after being challenged with SARS-CoV which were not seen in the lungs of challenged unvaccinated mice <xref rid="b0140" ref-type="bibr">[28]</xref>. Similar lung immunopathology was observed in several other studies, particularly in aged mice compared to younger mice <xref rid="b0145" ref-type="bibr">[29]</xref> that were challenged following vaccination <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>. Mice immunised with SARS-CoV N protein vaccine developed severe pneumonia or lung eosinophilic infiltrate upon viral challenge, whereas mice immunised with viral replicon particles expressing glycoprotein did not, suggesting that the N protein antigen may be the antigen linked to this immunopathology. Similar enhanced immunopathology has been seen in mice vaccinated with inactivated MERS-CoV vaccine when challenged with live virus <xref rid="b0160" ref-type="bibr">[32]</xref>. Vaccine associated disease enhancement may be more of a concern with certain vaccine types. Enhanced disease caused by viral challenge has been notable following administration of inactivated measles and RSV vaccines <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, with the possible mechanisms being a Th2 skewed response resulting from formalin inactivation as well as lack of affinity maturation of the antibodies produced <xref rid="b0175" ref-type="bibr">[35]</xref>.</p></sec><sec id="s0015"><title>SARS-CoV-2/COVID-19 vaccines:</title><sec id="s0020"><title>Context:</title><p id="p0040">Developing and scaling-up mass production of a vaccine rapidly in a global pandemic setting is challenging as it requires many activities to be well-coordinated and occurring in parallel, in contrast to the usual decade long, sequential process with pre-clinical testing, phased clinical trials, planned production and distribution. These challenges result in an aggregation of invested resources and elevated financial risk <xref rid="b0180" ref-type="bibr">[36]</xref>. In outbreaks, delay in vaccine distribution can result in considerable mortality and morbidity as illustrated by the 2013/2014 West African Ebola epidemic which killed more than 11,000 people <xref rid="b0185" ref-type="bibr">[37]</xref> and resulted in economic and social burden costing over 53 billion dollars <xref rid="b0190" ref-type="bibr">[38]</xref>. Tragically, a vaccine had been in development and was later shown to be effective in the prevention of Ebola and may have contributed to controlling the outbreak <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>. Unfortunately, the SARS 2003 epidemic ended before vaccine development was complete. Disappointingly, funding agencies then reallocated funds that had been committed to vaccine development, leaving manufacturers with financial loss and setting back other vaccine development programs <xref rid="b0180" ref-type="bibr">[36]</xref>. In 2017, the Coalition of Epidemic Preparedness Innovation (CEPI) was formed to address these past failures with a mission to develop a coordinated response to emerging infectious disease threats to ensure vaccine development and early deployment in response to epidemics <xref rid="b0205" ref-type="bibr">[41]</xref>.</p></sec></sec><sec id="s0025"><title>Diversity of technology platforms:</title><p id="p0045">One method for overcoming road blocks has been to through the use of new technology platforms to expedite vaccine development <xref rid="b0210" ref-type="bibr">[42]</xref>. Vaccines licensed in humans have traditionally been live attenuated viruses (e.g. Measles, mumps, rubella), inactivated viruses (e.g. inactivated polio vaccine) protein or polysaccharide conjugated subunit vaccines (protein: acellular pertussis, hepatitis B; polysaccharide conjugated: pneumococcus, meningococcus), and virus-like particles. Over the last decade, a range of new technology platforms have been developed and include vaccines composed of nucleic acid (DNA and RNA) and viral vectors and recombinant proteins.</p></sec><sec id="s0030"><title>Recombinant vaccines/viral vectors:</title><p id="p0050">Viral vector technology involves the delivery of one or more genes that encode a target antigen within an unrelated, engineered virus. The viral vector can be replication competent (live attenuated) or replication deficient. For HIV, Ebola, Zika and Chikungunya, vaccines using viral vectors including adenovirus (Ad), measles virus (MV), vesicular stomatitis virus (VSV), alphaviruses, poxviruses and herpesviruses allowing for insertion of 5 kb or more of the transgene have shown ability to stimulate cellular and humoral immunity <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>. Concerns with this platform are with the likely slower speed of vaccine manufacturing in an outbreak setting given the need for biosafety level 2 (BSL2) laboratories, and possible pre-existing immunity in vaccine recipients to viral vectors such as Ad5 and MV decreasing the effectiveness of the vaccine. Approaches such as the selection of low human prevalence adenoviral serotypes (Ad26 or Ad35) have been used to circumvent such an issue <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>. The recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) Ebola vaccine is currently the only vector-vaccine that has been licensed and available for human use, and only produced and used to a limited extent <xref rid="b0220" ref-type="bibr">[44]</xref>, <xref rid="b0225" ref-type="bibr">[45]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>.</p><p id="p0055">A MERS-CoV vaccine (MVA-MERS-S_DF1) using modified vaccinia virus Ankara and expressing the spike (S) protein of MERS-CoV was evaluated in an open label, phase 1 trial on 26 individuals aged 18-55. It showed a favourable safety profile without any severe adverse effects but induced only a relatively limited humoral and T-cell response to the MERS CoV <xref rid="b0235" ref-type="bibr">[47]</xref>. Reassuringly, the study showed that although vector specific neutralisation antibody was elicited, the vaccine still elicited antibody responses against the transgene following booster immunisation <xref rid="b0235" ref-type="bibr">[47]</xref>. Results of the phase 1 clinical trial for an alternate vaccine, ChAdOx1 MERS vaccine that uses a replication deficient simian adenoviral vector expressing the spike (S) protein in 24 individuals aged 18-50 years showed that a single dose was able to elicit both humoral and cellular responses against MERS CoV. The majority of solicited and unsolicited adverse events (AEs) reported by participants were mild or moderate and all were self-limiting, and there were no serious AEs related to vaccine administration, which supports progression into phase 1b and 2 trials <xref rid="b0240" ref-type="bibr">[48]</xref>.</p></sec><sec id="s0035"><title>Nucleic acid vaccines:</title><p id="p0060">Nucleic acid vaccines utilize antigen-encoding plasmid DNA or RNA, messenger RNA (mRNA) or viral replicons. The nucleic acid, once taken up by a cell will initiate protein synthesis, to which a humoral and cell-mediated immune response is expected to occur, similar to natural infection. Such vaccines have been trialled for veterinary infectious diseases and demonstrated immunogenicity, for example, for foot and mouth disease, deer powassan virus and rabies virus <xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>. Phase I trials in humans are underway for nucleic acid vaccines against Ebola, influenza and Zika virus <xref rid="b0210" ref-type="bibr">[42]</xref>. The benefit of a nucleic acid platform is the ease with which it allows antigen manipulation and the speed of production, as manufacturing can be synthetic and entirely cell free so circumventing the need for BSL2 laboratories. The disadvantages are that nucleic acid, especially mRNA, are fragile and require an uninterrupted cold-chain process for transport and storage <xref rid="b0260" ref-type="bibr">[52]</xref>. Phase I clinical trials have been conducted on SARS-CoV and MERS-CoV DNA vaccine candidates. A recombinant SARS DNA vaccine candidate coding for the SARS-CoV N protein genome, developed by the National Institute of Allergy and Infectious Diseases (NIAID) was investigated in 10 adults <xref rid="b0265" ref-type="bibr">[53]</xref>. A MERS-CoV DNA vaccine (GLS-5300), developed by GeneOne Life Science/Inovio and coding for the full length S protein genome, had a higher number of participants (n=75) <xref rid="b0270" ref-type="bibr">[54]</xref> Both showed acceptable safety profiles and induced humoral and cellular responses; the MERS-CoV DNA vaccine has advanced into a phase 2 clinical trial <xref rid="b0275" ref-type="bibr">[55]</xref>. The only other SARS vaccine to have entered a Phase I trial is an inactivated vaccine (ISCV) produced by Sinovac Biotech <xref rid="b0280" ref-type="bibr">[56]</xref>. There were no reports of human studies in which vaccinated subjects were challenged by the natural virus.</p></sec><sec id="s0040"><title>Vaccine Candidates:</title><p id="p0065">As of 1<sup>st</sup> June 2020, there are currently 124 candidate vaccines that are under development for prevention of COVID-19 listed by the WHO Health Organization (WHO) landscape summary <xref rid="b0285" ref-type="bibr">[57]</xref> of which 10 candidate vaccines specifically designed for prevention of COVID-19 (<xref rid="t0005" ref-type="table">Table 1</xref>
) have entered phase 1, combined phase 1/2 or phase 2 human clinical trials in adults. Most of these trials are enrolling healthy adults (from age 18 years) only, with the upper age limit of inclusion ranging from 50 to 60 years. Two trials are enrolling young participants, one from aged &#x02265;3 years and the other &#x02265;6 years with no upper age limit in both. One combined phase I/II trial includes older adults (up to age 85 years), while another early phase I trial has been extended in May 2020 to include also older adults (to age 99 years) <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Candidate COVID-19 vaccines currently in phase 1 or 2 human clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Platform</th><th>Description</th><th>Advantages</th><th>Disadvantages</th></tr></thead><tbody><tr><td><bold>Recombinant Viral vector</bold></td><td>Unrelated virus engineered to encode the target gene of the pathogen. Viral vectors can be replicating or non-replicating</td><td>Induces high cellular and humoral immune responses</td><td>Possible pre-existing immunity against vectorRisk of reversion to virulenceLimitations in scaling-up production</td></tr><tr><td><italic>Candidate vaccines:</italic></td><td colspan="3"><bold>Ad5-CoV</bold>Adenovirus Type 5 vector; antigen: Spike proteinPhase I: CanSino Biologics ChiCTR2000030906 <xref rid="b0440" ref-type="bibr">[88]</xref>/NCT04313127 <xref rid="b0445" ref-type="bibr">[89]</xref>Phase II: Institute of Biotechnology; Academy of Military Medical SciencesChiCTR2000031781 <xref rid="b0450" ref-type="bibr">[90]</xref>/NCT04341389 <xref rid="b0455" ref-type="bibr">[91]</xref>Participants: 18&#x02013;60 years; Phase I n=108Phase II: n=508<italic>Phase I: vaccine was safe and tolerable. No serious adverse effects. 63 participants (Low dose n=18 [50%); moderate dose n=18 [50%]; high dose n=27 [75%]) developed four fold rise in neutralising antibody titres by Day 28. Pre-existing immunity to Ad5 neutralising antibody titre was observed in half of the participants before vaccination. Out of these, a low proportion seroconverted</italic><xref rid="b0380" ref-type="bibr">[76]</xref>, <xref rid="b0005" ref-type="bibr">[1]</xref><bold>AZD1222 (previous known as ChAdOx1 nCoV-19)</bold>Simian adenoviral vaccine vector; antigen: Spike proteinPhase I/II: University of Oxford NCT04324606 <xref rid="b0460" ref-type="bibr">[92]</xref>Participants: 18-55 years; n= 1090</td></tr><tr><td><bold>Inactivated</bold></td><td>Pathogen virus inactivated by chemicals or radiation</td><td>Easy to prepareHigh safety</td><td>Variable efficacy</td></tr><tr><td><italic>Candidate vaccines:</italic></td><td colspan="3"><bold>PiCoVacc</bold>Phase I/II: Sinovac Biotech Co NCT04352608 <xref rid="b0465" ref-type="bibr">[93]</xref>Participants: 18-59 years; Phase I n=144; Phase II n=600Phase I/II: Sinovac Biotech Co NCT04383574 <xref rid="b0470" ref-type="bibr">[94]</xref>Participants: &#x02265;60 years; Phase I n=72; Phase II n=350<bold>Inactivated novel coronavirus vaccine</bold>Phase I/II: Beijing Institute of Biological Products/SinopharmChiCTR2000032459 <xref rid="b0475" ref-type="bibr">[95]</xref>Recruitment: Age &#x0003e;/= 3 years; Phase I n=480; Phase II n=1168<bold>Inactivated novel coronavirus vaccine</bold> Phase I/II: Wuhan Institute of Biological Products/SinopharmChiCTR2000031809 <xref rid="b0475" ref-type="bibr">[95]</xref>Participants: Age &#x0003e;/= 6 years; Phase I n=288; Phase II n=1168</td></tr><tr><td><bold>Live attenuated</bold></td><td>Live virus whose genome(s) is mutated, inducing immune response but not disease</td><td>Induces long-term immunity</td><td>Expensive to produce</td></tr><tr><td><italic>Candidate vaccines:</italic></td><td colspan="3">Nil in clinical trials as yet</td></tr><tr><td><bold>Protein subunit</bold></td><td>Components of target antigen protein produced in laboratory; some vaccines may use nanoparticle technology</td><td>High safetyScalability</td><td>High costLower immunogenicity and may require adjuvant or repeat doses</td></tr><tr><td><italic>Candidate vaccines:</italic></td><td colspan="3"><bold>NVX-CoV2373</bold>Phase I: Novovax NCT04368988 <xref rid="b0480" ref-type="bibr">[96]</xref>Participants: 18-59 years; n=131</td></tr><tr><td><bold>Virus like particle</bold></td><td>Non-infectious self- assembling viral structural proteins</td><td>Induces strong immune response</td><td>Limitations in manufacturing production</td></tr><tr><td><italic>Candidate vaccines:</italic></td><td colspan="3">Nil in clinical trial as yet</td></tr><tr><td><bold>mRNA</bold></td><td>mRNA encoding target antigen (may be complexed with lipid- or polymer-based nanoparticles)</td><td>Easier to designInduces strong immune responseRapid manufacture</td><td>Requires mRNA to be encapsulated otherwise unstable under physiological conditions</td></tr><tr><td><italic>Candidate vaccines:</italic></td><td colspan="3"><bold>BNT162</bold>Phase I/II: BioNTech/PfizerFour candidates, two candidates include a nucleoside modified mRNA, one a uridine containing mRNA and the fourth self- amplifying mRNA. Each combined with a lipid nanoparticle formulation.Germany 2020-001038-36 <xref rid="b0485" ref-type="bibr">[97]</xref>Participants: 18&#x02013;55 years; n=196USA NCT04368728 <xref rid="b0480" ref-type="bibr">[96]</xref>Participants: 18&#x02013;85 years; n=7600<bold>mRNA-1273Lipid nano-particle (LNP)-encapsulated mRNA vaccine;Coding antigen: full length S-protein</bold>Phase I/II: Moderna/National Institute of Allergy and infectious diseasesNCT04283461 <xref rid="b0295" ref-type="bibr">[59]</xref>Participants: 18-55 years, extended to 99 years n=155<italic>Interim Phase 1 Data: 15 participants seroconverted by day 15; 8 participants: all developed neutralizing antibodies</italic><xref rid="b0385" ref-type="bibr">[77]</xref></td></tr><tr><td><bold>DNA</bold></td><td>DNA that encodes the target antigen</td><td>Easier to designRapid manufacture</td><td>May require a special approach to administer the vaccine (e.g. electroporation device)May requires adjuvant Uncertainty of safety issues</td></tr><tr><td/><td colspan="3"><bold>INO-4800</bold>Phase I: Inovio Pharmaceuticals NCT04336410 <xref rid="b0490" ref-type="bibr">[98]</xref>Participants : 18-50 years n=40<bold>Plasmid DNA oral vaccine (bacTRL-IL-Spike-1)</bold>Phase 1: Symvivo NCT04334980 <xref rid="b0495" ref-type="bibr">[99]</xref>Participants: 19=55 years; n= 84</td></tr></tbody></table></table-wrap></p></sec><sec id="s0045"><title>Re-purposed vaccines of for COVID-19 or off target effects of other vaccines:</title><p id="p0070">Licensed vaccines such as BCG and oral polio vaccine have been shown to have nonspecific, modulatory effects on the immune system and provide protection against other infectious diseases <xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>. This has led to the suggestion that these vaccines may have an effect in the prevention of COVID-19 <xref rid="b0325" ref-type="bibr">[65]</xref>. Three multi-centred randomised controlled trials on BCG vaccine administration are underway in health care workers in Australia <xref rid="b0330" ref-type="bibr">[66]</xref>, Netherlands <xref rid="b0335" ref-type="bibr">[67]</xref> and South Africa <xref rid="b0340" ref-type="bibr">[68]</xref>. A measles vaccine trial to prevent COVID-19 in health care workers in Egypt has been registered <xref rid="b0290" ref-type="bibr">[58]</xref> and oral polio vaccines are being considered in the United States of America <xref rid="b0345" ref-type="bibr">[69]</xref>.</p></sec><sec id="s0050"><title>Discussion:</title><p id="p0075">Even if sustained immunity is attained after infection by SARS-CoV2, estimates are that 60-70% of a population would need to be immune to achieve herd immunity against SARS-CoV2 <xref rid="b0350" ref-type="bibr">[70]</xref>. The safest and most controlled way for effective and sustainable prevention of COVID-19 in a population is to have an efficacious and safe vaccine and the majority of the population successfully vaccinated. In addition, the vaccine should also be readily mass-produced inexpensively, and be easily transportable with minimal cold chain requirements to have global utility. Immunity after primary COVID-19 infection seems to protect against re-infection in primate models and is likely to occur in humans <xref rid="b0355" ref-type="bibr">[71]</xref>; whether this can be mimicked in vaccines and for how long immunity may last is still uncertain. Following SARS-CoV infection, IgG and Neutralising Ab was detectable for 1 to 3 years following infection which suggests that vaccine-induced protection is unlikely to be long-lasting and may require re-immunization <xref rid="b0360" ref-type="bibr">[72]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0370" ref-type="bibr">[74]</xref>, <xref rid="b0375" ref-type="bibr">[75]</xref>.</p><p id="p0080">The rapid progression of new vaccine candidates against SARS-CoV-2 into pre-clinical and clinical studies is encouraging. Several phase 1 trial results have recently been released. Ad5-CoV vaccine, conducted in 108 participants showed reasonable safety or tolerability profile and has now progressed to phase II. Humoral and cell mediated responses were seen in participants, albeit less in those with pre-existing Ad5 vector immunity <xref rid="b0380" ref-type="bibr">[76]</xref>. Interim phase 1 data, released on May 18 on mRNA-1273 demonstrated seroconversion and development of neutralizing antibodies in 8 individuals <xref rid="b0385" ref-type="bibr">[77]</xref>. It is an open question of whether these candidates will display the necessary efficacy and safety profile in humans to progress further into phase 3 trials and subsequently licensure and use to control COVID-19 transmission. In a review of 11 epidemic infectious diseases, only 1 out of 11 (21 preclinical vaccine candidates) have been shown to go through to end of phase 2a trials, at the estimated cost of USD $319-469 million (range $137 million to $1.1 billion) <xref rid="b0390" ref-type="bibr">[78]</xref>. In the current climate, some vaccine developers are have shown willingness to start or progress later phase trial preparations even before definitive results of earlier phase trials are available <xref rid="b0395" ref-type="bibr">[79]</xref>.</p><p id="p0085">There have been international collaborative efforts to expedite vaccine development and production. The prior establishment of CEPI has been an integral existing platform that has supported the rapid development of COVID-19 vaccines without having to establish new mechanisms with attendant costs. CEPI is supporting the nine COVID-19 vaccine candidates briefly presented here. Since its formation it has established measures to finance early development of vaccines, up to phase 3 clinical trials. However, it does not have a role in the manufacturing or deployment of vaccines and a consortium of public and philanthropic funders will be required for complete preparedness for vaccine manufacture and delivery.</p><p id="p0090">In addition to CEPI, the WHO and the U.S. National Institutes of Health (NIH) are contributing to global collaborative efforts to accelerate vaccine development. The WHO Solidarity Trial for vaccines is a large, multi-site individually randomised controlled clinical trial to allow evaluation of the benefits and risks of each COVID-19 candidate vaccines within 3&#x02013;6 months <xref rid="b0400" ref-type="bibr">[80]</xref>. Further, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), an international public-private partnership, has been established to co-ordinate and speed up the response to the COVID-19 pandemic. Government organisations (in the US and one in Europe), international biopharmaceutical companies and a non-profit organisation are all involved in advancing vaccine development <xref rid="b0405" ref-type="bibr">[81]</xref>.</p><p id="p0095">Vaccine efficacy in under-represented and vulnerable populations also remains an issue. A majority of vaccine trials have focused on healthy people between the ages of 18-65 years, excluding the elderly, pregnant women and children. Given the disproportionate mortality rate in people over the age of 60, the elderly need to be considered in vaccine trials to ensure safety, immunogenicity and efficacy data is collected and are prioritised to receive COVID-19 vaccines in outbreak situations. Pregnancy has not been shown to be a risk factor for disease severity and the disease burden is low in children. However, much is still unknown, especially the role of inducing an adaptive auto-inflammatory response such as Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS). There is an urgent need for a better understanding of the immunopathogenesis of COVID-19 to give guidance to the immunological assessment of vaccine responses.</p><p id="p0100">There has never been a more rapid pace to vaccine development. The pandemic situation has been a challenge and a trigger to reconsidering the usual approaches to regulatory assessment and licensing processes. Vaccine companies are showing willingness to commit to scaled-up production prior to definitive phase 3 trial results <xref rid="b0395" ref-type="bibr">[79]</xref>. The implementation of high quality, aligned surveillance for COVID-19 across multiple regions concurrently with vaccine deployment is critical both for evaluating the real-world effectiveness of a new vaccine against SARS-CoV-2, but also for monitoring its safety in so-call &#x02018;post-marketing&#x02019; surveillance. The association of rotavirus vaccines with intussusception in children was only detected following licensure and deployment of these vaccines <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>., the experience of the Philippines with a novel Dengue vaccine should also promote a degree of caution with respect to vaccine safety during their population usage even if they appear safe in phase 1, 2 and 3 studies. <xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0425" ref-type="bibr">[85]</xref> There will be considerable uncertainties regarding the safety of vaccines for COVID-19 given the new vaccine platforms used without prior licensed examples, deployment to population subgroups not included in trials of that particular candidate), additional uncertainty arising from novel adjuvants in quite a number of candidates.</p><p id="p0105">As we have alluded to, the development of a vaccine that shows efficacy in clinical trials is only the beginning of a process to manufacture, deploy and monitor the effectiveness of a new vaccine. The challenges ahead are numerous. As an example, in 2016 as part of the Global Poliovirus Eradication Initiative (GPEI), 155 countries were planned to synchronously shift from trivalent oral polio vaccine (tOPV) to bivalent vaccine (bOPV) <xref rid="b0430" ref-type="bibr">[86]</xref>. This switch was to be coordinated with concurrent inclusion of at least 1 dose of inactivated polio vaccine (IPV) into routine immunization schedules in 126 OPV using countries. Significant difficulties have been encountered with vaccine manufacturing and supply chains resulting in interruptions and delays in multiple countries <xref rid="b0435" ref-type="bibr">[87]</xref>. This experience will certainly inform and improve a potential global COVID-19 vaccine deployment, but should influence a level of caution with respect to our expectations even were an effective vaccine developed.</p><p id="p0110">Despite efforts in fast tracking vaccine development, completion dates for early clinical trials are estimated to be late 2020 to mid-2021 and it may still take longer before a vaccine is licensed for use globally, although the pandemic has triggered reconsideration of the usual approaches to regulatory assessment and licensing. This emphasises the need for proven public health strategies such as physical distancing, early detection, self-isolation and outbreak control remain as important mitigation tools.</p></sec><sec id="s0055"><title>Educational Aims:</title><p id="p0115">The reader will be able to:<list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0120">Understand of the types of vaccine and vaccine platforms being developed for SARS-CoV-2.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0125">Develop knowledge regarding the concerns around coronavirus vaccine development.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0130">Appreciated the issues of rapid vaccine development in outbreak settings.</p></list-item></list>
</p></sec><sec id="s0060"><title>Future research directions:</title><p id="p0135">
<list list-type="simple" id="l0010"><list-item id="o0020"><label>&#x02022;</label><p id="p0140">Ongoing progress of candidate vaccines through preclinical and clinical studies.</p></list-item><list-item id="o0025"><label>&#x02022;</label><p id="p0145">Ongoing detailed characterisation of the immunopathogenesis of COVID-19.</p></list-item><list-item id="o0030"><label>&#x02022;</label><p id="p0150">Implementation of large scale post marketing surveillance systems to monitor SARS-CoV2 vaccine safety.</p></list-item></list>
</p></sec></body><back><ref-list id="bi005"><title>References:</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>New England Journal of Medicine</source><year>2020</year></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="b0015"><label>3</label><mixed-citation publication-type="other" id="h0015">Centre for Systems Science and Engineering. COVID-19 Dashboard. 2020 [cited 2020 June 3, 2020]; Available from: https://coronavirus.jhu.edu/map.html.</mixed-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.-J.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>New England journal of medicine</source><volume>382</volume><issue>18</issue><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>The Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>507</fpage><lpage>513</lpage></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Bhatraju</surname><given-names>P.K.</given-names></name></person-group><article-title>Covid-19 in critically ill patients in the Seattle region&#x02014;case series</article-title><source>New England Journal of Medicine</source><year>2020</year></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan</article-title><source><italic>China.</italic> Jama</source><volume>323</volume><issue>11</issue><year>2020</year><fpage>1061</fpage><lpage>1069</lpage></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L.</given-names></name></person-group><article-title>Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study</article-title><source>The American journal of gastroenterology</source><volume>115</volume><year>2020</year></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan</article-title><source><italic>China.</italic> The lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Giacomelli</surname><given-names>A.</given-names></name></person-group><article-title>Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study</article-title><source>Clinical Infectious Diseases</source><year>2020</year></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.</given-names></name></person-group><article-title>SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19</article-title><source>Gut</source><volume>69</volume><issue>6</issue><year>2020</year><fpage>1143</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">32139552</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Recalcati</surname><given-names>S.</given-names></name></person-group><article-title>Cutaneous manifestations in COVID-19: a first perspective</article-title><source>Journal of the European Academy of Dermatology and Venereology</source><year>2020</year></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>S.A.</given-names></name></person-group><article-title>The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</article-title><source>Annals of internal medicine</source><year>2020</year></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L.</given-names></name></person-group><article-title>SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients</article-title><source>New England Journal of Medicine</source><volume>382</volume><issue>12</issue><year>2020</year><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">32074444</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.</given-names></name></person-group><article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title><source>Nature medicine</source><year>2020</year><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>The lancet</source><year>2020</year></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>18</volume><issue>4</issue><year>2020</year><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">32073213</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.-J.</given-names></name></person-group><article-title>Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis</article-title><source>European Respiratory Journal</source><year>2020</year><fpage>2000547</fpage><pub-id pub-id-type="pmid">32217650</pub-id></element-citation></ref><ref id="b0100"><label>20</label><mixed-citation publication-type="other" id="h0100">Oke, J. and C. Heneghan. Global COVID-19 Case Fatality Rates. 2002 19 May 2020 [cited 2020 24 May 2020]; Available from: https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/.</mixed-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>P.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children</article-title><source>The Pediatric Infectious Disease Journal</source><volume>39</volume><issue>5</issue><year>2020</year><fpage>355</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">32310621</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Boopathi</surname><given-names>S.</given-names></name><name><surname>Poma</surname><given-names>A.B.</given-names></name><name><surname>Kolandaivel</surname><given-names>P.</given-names></name></person-group><article-title>Novel coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment</article-title><source>Journal of Biomolecular Structure and Dynamics</source><volume>2020</volume><year>2019</year><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><issue>26</issue><year>2004</year><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="pmid">15210961</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Roper</surname><given-names>R.L.</given-names></name><name><surname>Rehm</surname><given-names>K.E.</given-names></name></person-group><article-title>SARS vaccines: where are we?</article-title><source>Expert Rev Vaccines</source><volume>8</volume><issue>7</issue><year>2009</year><fpage>887</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">19538115</pub-id></element-citation></ref><ref id="b0130"><label>26</label><mixed-citation publication-type="other" id="h0130">Edridge, A., et al., Human coronavirus reinfection dynamics: lessons for SARS-CoV-2. 2020.</mixed-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Donaldson</surname><given-names>E.F.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A decade after SARS: strategies for controlling emerging coronaviruses</article-title><source>Nature reviews. Microbiology</source><volume>11</volume><issue>12</issue><year>2013</year><fpage>836</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">24217413</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C.-T.</given-names></name></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PloS one</source><year>2012</year><fpage>7(4)</fpage></element-citation></ref><ref id="b0145"><label>29</label><mixed-citation publication-type="other" id="h0145">Deming, D., et al., Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS medicine, 2006. 3(12): p. e525-e525.</mixed-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Bolles</surname><given-names>M.</given-names></name></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>Journal of virology</source><volume>85</volume><issue>23</issue><year>2011</year><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="pmid">21937658</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>F.</given-names></name></person-group><article-title>Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV</article-title><source>The Journal of Immunology</source><volume>181</volume><issue>9</issue><year>2008</year><fpage>6337</fpage><lpage>6348</lpage><pub-id pub-id-type="pmid">18941225</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A.S.</given-names></name></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Human Vaccines &#x00026; Immunotherapeutics</source><volume>12</volume><issue>9</issue><year>2016</year><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="pmid">27269431</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>J.</given-names></name></person-group><article-title>Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population</article-title><source>Am J Epidemiol</source><volume>89</volume><issue>4</issue><year>1969</year><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">4305200</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.W.</given-names></name></person-group><article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title><source>Am J Epidemiol</source><volume>89</volume><issue>4</issue><year>1969</year><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">4305198</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Delgado</surname><given-names>M.F.</given-names></name></person-group><article-title>Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease</article-title><source>Nature medicine</source><volume>15</volume><issue>1</issue><year>2009</year><fpage>34</fpage><lpage>41</lpage></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>N.</given-names></name></person-group><article-title>Developing Covid-19 Vaccines at Pandemic Speed</article-title><source>New England Journal of Medicine</source><volume>382</volume><issue>21</issue><year>2020</year><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>WHO Ebola Response Team</surname></name></person-group><article-title>After Ebola in West Africa &#x02014; Unpredictable Risks, Preventable Epidemics</article-title><source>New England Journal of Medicine</source><volume>375</volume><issue>6</issue><year>2016</year><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">27509108</pub-id></element-citation></ref><ref id="b0190"><label>38</label><mixed-citation publication-type="other" id="h0190">Huber, C., L. Finelli, and W. Stevens, The Economic and Social Burden of the 2014 Ebola Outbreak in West Africa. The Journal of Infectious Diseases, 2018. 218(Supplement_5): p. S698-S704.</mixed-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S.M.</given-names></name></person-group><article-title>Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses</article-title><source>Nature Medicine</source><volume>11</volume><issue>7</issue><year>2005</year><fpage>786</fpage><lpage>790</lpage></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Henao-Restrepo</surname><given-names>A.M.</given-names></name></person-group><article-title>Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola &#x000c7;a Suffit!)</article-title><source>The Lancet</source><volume>389</volume><issue>10068</issue><year>2017</year><fpage>505</fpage><lpage>518</lpage></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Brende</surname><given-names>B.</given-names></name></person-group><article-title>CEPI&#x02014;a new global R&#x00026;D organisation for epidemic preparedness and response</article-title><source>The Lancet</source><volume>389</volume><issue>10066</issue><year>2017</year><fpage>233</fpage><lpage>235</lpage></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S.</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Frontiers in immunology</source><volume>9</volume><year>2018</year><fpage>1963</fpage><pub-id pub-id-type="pmid">30283434</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>Replicating and non-replicating viral vectors for vaccine development</article-title><source>Current opinion in biotechnology</source><volume>18</volume><issue>6</issue><year>2007</year><fpage>546</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">18063357</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Regules</surname><given-names>J.A.</given-names></name></person-group><article-title>A Recombinant Vesicular Stomatitis Virus Ebola Vaccine</article-title><source>N Engl J Med</source><volume>376</volume><issue>4</issue><year>2017</year><fpage>330</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">25830322</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>S.B.</given-names></name></person-group><article-title>Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia</article-title><source>New England Journal of Medicine</source><volume>377</volume><issue>15</issue><year>2017</year><fpage>1438</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">29020589</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="book" id="h0230"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><chapter-title>Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response</chapter-title><year>2019</year><publisher-name>The Organization</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>T.</given-names></name></person-group><article-title>Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial</article-title><source>The Lancet Infectious Diseases</source><year>2020</year></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name><surname>Folegatti</surname><given-names>P.M.</given-names></name></person-group><article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</article-title><source>The Lancet Infectious Diseases</source><year>2020</year></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name><surname>Pulido</surname><given-names>M.R.</given-names></name></person-group><article-title>RNA immunization can protect mice against foot-and-mouth disease virus</article-title><source>Antiviral research</source><volume>85</volume><issue>3</issue><year>2010</year><fpage>556</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">20005905</pub-id></element-citation></ref><ref id="b0250"><label>50</label><mixed-citation publication-type="other" id="h0250">VanBlargan, L.A., et al., An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell reports, 2018. 25(12): p. 3382-3392. e3.</mixed-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>S.</given-names></name></person-group><article-title>Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein</article-title><source>Veterinary microbiology</source><volume>136</volume><issue>1&#x02013;2</issue><year>2009</year><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">19081687</pub-id></element-citation></ref><ref id="b0260"><label>52</label><mixed-citation publication-type="other" id="h0260">Zhang, C., et al., Advances in mRNA Vaccines for Infectious Diseases. Frontiers in Immunology, 2019. 10(594).</mixed-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.E.</given-names></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><issue>50</issue><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">18824060</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name><surname>Modjarrad</surname><given-names>K.</given-names></name></person-group><article-title>Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial</article-title><source>The Lancet Infectious Diseases</source><volume>19</volume><issue>9</issue><year>2019</year><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">31351922</pub-id></element-citation></ref><ref id="b0275"><label>55</label><mixed-citation publication-type="other" id="h0275">ClinicalTrials.gov. Identifier: NCT03721718. Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT03721718.</mixed-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title><source>Antiviral therapy</source><volume>12</volume><issue>7</issue><year>2007</year><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">18018769</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><article-title>DRAFT landscape of COVID-19 candidate vaccines</article-title><source>World</source><year>2020</year></element-citation></ref><ref id="b0290"><label>58</label><mixed-citation publication-type="other" id="h0290">ClinicalTrials.gov. Identifier: NCT04357028. Measles Vaccine in HCW (MV-COVID19) 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT04357028.</mixed-citation></ref><ref id="b0295"><label>59</label><mixed-citation publication-type="other" id="h0295">ClinicalTrials.gov. Identifier: NCT04283461. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) 2020 May 4, 2020 [cited 2020 May 25, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04283461.</mixed-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name><surname>Goodridge</surname><given-names>H.S.</given-names></name></person-group><article-title>Harnessing the beneficial heterologous effects of vaccination</article-title><source>Nature Reviews Immunology</source><volume>16</volume><issue>6</issue><year>2016</year><fpage>392</fpage><lpage>400</lpage></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>A.J.</given-names></name><name><surname>Finn</surname><given-names>A.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>Non-specific effects of vaccines: plausible and potentially important, but implications uncertain</article-title><source>Archives of Disease in Childhood</source><volume>102</volume><issue>11</issue><year>2017</year><fpage>1077</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">28501809</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name><surname>Biering-S&#x000f8;rensen</surname><given-names>S.</given-names></name></person-group><article-title>Early BCG-Denmark and neonatal mortality among infants weighing&#x0003c; 2500 g: a randomized controlled trial</article-title><source>Clinical Infectious Diseases</source><volume>65</volume><issue>7</issue><year>2017</year><fpage>1183</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">29579158</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name><surname>Upfill-Brown</surname><given-names>A.</given-names></name></person-group><article-title>Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants</article-title><source>Clin Infect Dis</source><volume>65</volume><issue>3</issue><year>2017</year><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">28444240</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P.</given-names></name></person-group><article-title>Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries</article-title><source>BMJ</source><volume>311</volume><issue>7003</issue><year>1995</year><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">7647643</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>Considering BCG vaccination to reduce the impact of COVID-19</article-title><source>The Lancet</source><year>2020</year></element-citation></ref><ref id="b0330"><label>66</label><mixed-citation publication-type="other" id="h0330">ClinicalTrials.gov. Identifier: NCT04327206. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT04327206.</mixed-citation></ref><ref id="b0335"><label>67</label><mixed-citation publication-type="other" id="h0335">ClinicalTrials.gov. Identifier: NCT04328441. Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA); Available from: https://clinicaltrials.gov/ct2/show/NCT04328441.</mixed-citation></ref><ref id="b0340"><label>68</label><mixed-citation publication-type="other" id="h0340">ClinicalTrials.gov. Identifier: NCT04379336. BCG Vaccination for Healthcare Workers in COVID-19 Pandemic 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT04379336.</mixed-citation></ref><ref id="b0345"><label>69</label><mixed-citation publication-type="other" id="h0345">Global Polio Eradication Initiative. The use of oral polio vaccine (OPV) to prevent SARS-CoV2. 2020 [cited 2020 24 May 2020]; Available from: http://polioeradication.org/wp-content/uploads/2020/03/Use-of-OPV-and-COVID-20200421.pdf.</mixed-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>H.E.</given-names></name><name><surname>Barreiro</surname><given-names>L.B.</given-names></name></person-group><article-title>Herd Immunity: Understanding COVID-19</article-title><source>Immunity</source><volume>52</volume><issue>5</issue><year>2020</year><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">32433946</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L.</given-names></name></person-group><article-title>Reinfection could not occur in SARS-CoV-2 infected rhesus macaques</article-title><source>BioRxiv</source><year>2020</year></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.-P.</given-names></name></person-group><article-title>Duration of antibody responses after severe acute respiratory syndrome</article-title><source>Emerging infectious diseases</source><volume>13</volume><issue>10</issue><year>2007</year><fpage>1562</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">18258008</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome</article-title><source>The Journal of infectious diseases</source><volume>193</volume><issue>6</issue><year>2006</year><fpage>792</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">16479513</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W.-C.</given-names></name></person-group><article-title>Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery</article-title><source>New England Journal of Medicine</source><volume>357</volume><issue>11</issue><year>2007</year><fpage>1162</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">17855683</pub-id></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients</article-title><source>Scand J Infect Dis</source><volume>43</volume><issue>6&#x02013;7</issue><year>2011</year><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">21366405</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F.-C.</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>The Lancet</source><year>2020</year></element-citation></ref><ref id="b0385"><label>77</label><mixed-citation publication-type="other" id="h0385">Moderna, Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. 2020, Moderna, Inc.</mixed-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name><surname>Gouglas</surname><given-names>D.</given-names></name></person-group><article-title>Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study</article-title><source>The Lancet. Global health</source><volume>6</volume><issue>12</issue><year>2018</year><fpage>e1386</fpage><lpage>e1396</lpage><pub-id pub-id-type="pmid">30342925</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 vaccine development pipeline gears up</article-title><source>The Lancet</source><volume>395</volume><issue>10239</issue><year>2020</year><fpage>1751</fpage><lpage>1752</lpage></element-citation></ref><ref id="b0400"><label>80</label><mixed-citation publication-type="other" id="h0400">World Health Organisation. Update on WHO Solidarity Trial &#x02013; Accelerating a safe and effective COVID-19 vaccine. 2020 [cited 2020 May 24, 2020]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine.</mixed-citation></ref><ref id="b0405"><label>81</label><mixed-citation publication-type="other" id="h0405">National Institutes of Health. NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options. 2020 April 17, 2020 [cited 2020 May 24, 2020]; Available from: https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options.</mixed-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name><surname>Parashar</surname><given-names>U.D.</given-names></name></person-group><article-title>Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines</article-title><source>Vaccine</source><volume>33</volume><issue>Suppl 4</issue><year>2015</year><fpage>D55</fpage><lpage>D59</lpage><pub-id pub-id-type="pmid">26122581</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>C.</given-names></name></person-group><article-title>Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries</article-title><source>Human vaccines &#x00026; immunotherapeutics</source><volume>12</volume><issue>10</issue><year>2016</year><fpage>2580</fpage><lpage>2589</lpage><pub-id pub-id-type="pmid">27322835</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>H.J.</given-names></name><name><surname>Hartigan-Go</surname><given-names>K.</given-names></name><name><surname>de Figueiredo</surname><given-names>A.</given-names></name></person-group><article-title>Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness</article-title><source>Hum Vaccin Immunother</source><volume>15</volume><issue>3</issue><year>2019</year><fpage>625</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">30309284</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name><surname>de Bruin</surname><given-names>Y.B.</given-names></name></person-group><article-title>Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic</article-title><source>Safety Science</source><year>2020</year><object-id pub-id-type="publisher-id">104773</object-id></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="book" id="h0430"><person-group person-group-type="author"><name><surname>World Health</surname></name></person-group><chapter-title>Organization and Global Polio Eradication Initiative, <italic>Polio endgame strategy 2019&#x02013;2023: eradication, integration, certification and containment</italic></chapter-title><year>2019</year><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>I.</given-names></name></person-group><article-title>A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market</article-title><source>The Journal of Infectious Diseases</source><volume>216</volume><issue>suppl_1</issue><year>2017</year><fpage>S33</fpage><lpage>S39</lpage><pub-id pub-id-type="pmid">28838159</pub-id></element-citation></ref><ref id="b0440"><label>88</label><mixed-citation publication-type="other" id="h0440">Chinese Clinical Trial Registry. ChiCTR2000030906 A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector) 2020 [cited 2020 25 May 2020]; Available from: http://www.chictr.org.cn/showprojen.aspx?proj=51154.</mixed-citation></ref><ref id="b0445"><label>89</label><mixed-citation publication-type="other" id="h0445">ClinicalTrials.gov. Identifier: NCT04313127. Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (CTCOVID-19) 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04313127.</mixed-citation></ref><ref id="b0450"><label>90</label><mixed-citation publication-type="other" id="h0450">Chinese Clinical Trial Registry. ChiCTR2000031781 A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) 2020 [cited 2020 25 May 2020]; Available from: http://www.chictr.org.cn/showprojen.aspx?proj=52006.</mixed-citation></ref><ref id="b0455"><label>91</label><mixed-citation publication-type="other" id="h0455">ClinicalTrials.gov. Identifier: NCT04341389. A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV) 2020 [cited 2020 May 25 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04341389.</mixed-citation></ref><ref id="b0460"><label>92</label><mixed-citation publication-type="other" id="h0460">ClinicalTrials.gov. Identifier: NCT04324606. A Study of a Candidate COVID-19 Vaccine (COV001) 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04324606.</mixed-citation></ref><ref id="b0465"><label>93</label><mixed-citation publication-type="other" id="h0465">ClinicalTrials.gov. Identifier: NCT04352608. Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) 2020 April 28, 2020 [cited 2020 May 25, 2020].</mixed-citation></ref><ref id="b0470"><label>94</label><mixed-citation publication-type="other" id="h0470">ClinicalTrials.gov. Identifier: NCT04383574. Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) 2020 12 May 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04383574.</mixed-citation></ref><ref id="b0475"><label>95</label><mixed-citation publication-type="other" id="h0475">Chinese Clinical Trial Registry. ChiCTR2000031809 A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) 2020 April 13, 2020 [cited 2020 May 25, 2020]; Available from: http://www.chictr.org.cn/showprojen.aspx?proj=52227.</mixed-citation></ref><ref id="b0480"><label>96</label><mixed-citation publication-type="other" id="h0480">ClinicalTrials.gov. Identifier: NCT04368988. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant 2020 May 15, 2020 [cited 2020 May 25, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04368988.</mixed-citation></ref><ref id="b0485"><label>97</label><mixed-citation publication-type="other" id="h0485">EU Clinical Trials Register. EudraCT Number: 2020-001038-36. A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens 2020 April 20, 2020 [cited 2020 May 25, 2020]; Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-001038-36.</mixed-citation></ref><ref id="b0490"><label>98</label><mixed-citation publication-type="other" id="h0490">ClinicalTrials.gov. Identifier: NCT04336410. 2020 April 24, 2020 [cited 2020 May 2, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04336410.</mixed-citation></ref><ref id="b0495"><label>99</label><mixed-citation publication-type="other" id="h0495">ClinicalTrials.gov. Identifier: NCT04334980. 2020 April 22, 2020 [cited 2020 May 25, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04334980.</mixed-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.Y.-P.</given-names></name></person-group><article-title>Serological Approaches for COVID- 19: Epidemiologic Perspective on Surveillance and Control</article-title><source>Frontiers in Immunology</source><year>2020</year><fpage>11(879)</fpage><pub-id pub-id-type="pmid">32082309</pub-id></element-citation></ref></ref-list></back></article>